NEJM: Treatment effect of Enpagliflozin in patients with heart failure with normal ejection fraction

Sodium-glucose cotransporter 2 inhibitors can reduce the risk of hospitalization for heart failure patients with heart failure with reduced ejection fraction, but its effect on heart failure patients with normal ejection fraction is not yet clear
.

Recently, a research article was published in the top medical journal NEJM.
In this double-blind trial, in addition to conventional treatment, researchers also randomly assigned 5988 patients with grade II-IV heart failure with an ejection fraction of more than 40% to receive Enpagliflozin (10mg, once a day) or placebo treatment
.

Within a median time of 26.
2 months, 415 (13.
8%) of the 2997 patients in the empagliflozin group and 511 (17.
1%) of the 2991 patients in the placebo group had a major outcome event (hazard ratio of 0.
79).
; 95% confidence interval (CI) is 0.
69 to 0.
90; P<0.
001)
.

The effects of empagliflozin appear to be consistent in patients with or without diabetes
.

It can be seen that empagliflozin reduces the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with normal ejection fraction, regardless of whether they are accompanied by diabetes
.

Original source:
 
Stefan D.